Drug repositioning as a route to anti-malarial drug discovery: Preliminary investigation of the in vitro anti-malarial efficacy of emetine dihydrochloride hydrate

Malaria Journal

Volumn 12, Issue 1, 2013, Pages

  Matthews, Holly ^a   Usman Idris, Maryam ^a   Khan, Farid ^b   Read, Martin ^c   Nirmalan, Niroshini ^a  

^a UNIVERSITY OF SALFORD   (United Kingdom)

^b Lumophore Ltd   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Antimalarial chemotherapy; Dihydroartemisinin; Drug repositioning; Drug susceptibility assays; Emetine; Flow cytometry

Indexed keywords

DIHYDROARTEMISININ; EMETINE;

ANTIMALARIAL DRUG SUSCEPTIBILITY; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTINUOUS CULTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG INTERACTION; DRUG REPOSITIONING; DRUG RESEARCH; DRUG SCREENING; DRUG SYNTHESIS; FLOW CYTOMETRY; GIEMSA STAIN; IC 50; IN VITRO STUDY; MICROTITER PLATE ASSAY; MONOTHERAPY; NONHUMAN; PLASMODIUM FALCIPARUM; RELIABILITY;

ANTIMALARIALS; DRUG REPOSITIONING; EMETINE; HIGH-THROUGHPUT SCREENING ASSAYS; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM;

EID: 84885147970     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-12-359     Document Type: Article

References (36)

1. Antimalarial combinations. Kremsner PG, Krishna S, Lancet 2004 364 285 294 10.1016/S0140-6736(04)16680-4 15262108 (Pubitemid 38942820)
2. World Health Organization, Global report on antimalarial drug efficacy and drug resistance: 2000-2010 Geneva: WHO 2010
3. Artemisinin resistance: current status and scenarios for containment. Dondorp AM, Yeung S, White L, Nguon C, Day NPJ, Socheat D, Von Seidlein L, Nat Rev Micro 2010 8 272 280
4. Pitfalls in new artemisinin-containing antimalarial drug development. Jambou R, Le Bras J, Randrianarivelojosia M, Trends Parasitol 2011 27 82 90 10.1016/j.pt.2010.09.004 21030307
5. A novel artemisinin-quinine hybrid with potent antimalarial activity. Walsh JJ, Coughlan D, Heneghan N, Gaynor C, Bell A, Bioorg Med Chem Lett 2007 17 3599 3602 10.1016/j.bmcl.2007.04.054 17482816 (Pubitemid 46898817)
6. Antimalarial drug resistance. White NJ, J Clin Invest 2004 113 1084 1092 15085184 (Pubitemid 38544090)
7. Drug repositioning: identifying and developing new uses for existing drugs. Ashburn TT, Thor KB, Nat Rev Drug Discov 2004 3 673 683 10.1038/nrd1468 15286734 (Pubitemid 39173508)
8. In silico repositioning of approved drugs for rare and neglected diseases. Ekins S, Williams AJ, Krasowski MD, Freundlich JS, Drug Discov Today 2011 16 298 310 10.1016/j.drudis.2011.02.016 21376136
9. The role of thalidomide in the management of erythema nodosum leprosum. Walker SL, Waters MF, Lockwood DN, Lepr Rev 2007 78 197 215 18035771 (Pubitemid 351171817)
10. Sildenafil for male erectile dysfunction: a systematic review and meta-analysis. Fink HA, Mac Donald R, Rutks IR, Nelson DB, Wilt TJ, Arch Intern Med 2002 162 1349 1360 10.1001/archinte.162.12.1349 12076233 (Pubitemid 34655194)
11. Cost of innovation in the pharmaceutical industry. DiMasa JA, Hansen RW, Grabowski HG, Lasagna L, J Health Econ 1991 10 107 142 10.1016/0167-6296(91) 90001-4 10113009
12. Complementary new approaches enable repositioning of failed drug candidates. Tartaglia LA, Expert Opin on Investig Drugs 2006 15 1295 1298 10.1517/13543784.15.11.1295 (Pubitemid 44615280)
13. Drug repositioning in the treatment of malaria and TB. Nzila A, Ma Z, Chibale K, Future Med Chem 2011 3 1413 1426 10.4155/fmc.11.95 21879845
14. Challenges in antimalarial drug discovery. Burrows JN, Leroy D, Lotharius J, Waterson D, Future Med Chem 2011 3 1401 1412 10.4155/fmc.11.91 21879844
15. Discovery of potent small molecule inhibitors of multi drug-resistant Plasmodium falciparum using a novel miniaturised high throughput luciferase-based assay. Lucumi E, Darling C, Jo H, Napper AD, Chandramohandas R, Fisher N, Shone AE, Jing H, Ward SA, Biagini GA, DeGrado WF, Diamond SL, Greenbaum DC, Antimicrob Agents Chemother 2010 54 3579 3604
16. Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised multicentre trial. Adjuik M, Agnamey P, Babiker A, Borrmann S, Brasseur P, Cisse M, Cobelens F, Diallo S, Faucher JF, Garner P, Gikunda S, Kremsner PG, Krishna S, Lell B, Loolpapit M, Matsiegui PB, Missinou MA, Mwanza J, Ntoumi F, Olliaro P, Osimbo P, Rezbach P, Some E, Taylor WR, Lancet 2002 359 1365 1372 10.1016/S0140-6736(02)08348-4 11978332 (Pubitemid 34442375)
17. Amodiaquine alone, amodiaquine + sulfodoxine-pyremethamin, amodiaquine + artesunate and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four armed randomised effectiveness trial. Mutabingwa TK, Anthony D, Heller A, Hallett R, Ahmed J, Drakeley C, Greenwood BM, Whitty CJ, Lancet 2005 365 1474 1480 10.1016/S0140-6736(05)66417-3 15850631 (Pubitemid 40591692)
18. World Health Organization, Antimalarial drug combination therapy (WHO/CDS/RBM/2001.35) Geneva: WHO 2001
19. Simple in vitro culture of the malaria parasite Plasmodium falciparum (erythrocytic stages): suitable for large-scale preparations. Read M, Hyde JE, Protocols in Molecular Parasitology. (Hyde JE Ed.). Volume 21 1993 43 55
20. Human malaria parasites in continuous culture. Trager W, Jensen JB, Science 1976 193 673 675 10.1126/science.781840 781840
21. Antimalarial pharmacodynamics of chalcone derivatives in combination with artemisninin against Plasmodium falciparum in vitro. Bhattacharya A, Mishra LC, Sharma M, Awasthi SK, Bhasin VK, Eur J Med Chem 2009 44 3388 3393 10.1016/j.ejmech.2009.02.008 19269069
22. The SYBR Green I malaria drug sensitivity assay: performance in low parasitaemia samples. Vossen MG, Pferschy S, Chiba P, Noedl H, Am J Trop Med Hyg 2010 82 398 401 10.4269/ajtmh.2010.09-0417 20207863
23. Performance and reliability of the SYBR Green 1 based assay for the routine monitoring of susceptibility of Plasmodium falciparum in clinical isolates. Rason MA, Randriantsoa T, Andrianantenaina H, Ratsimbasoa A, Menard D, Trans R Soc Trop Med Hyg 2008 102 346 351 10.1016/j.trstmh.2008.01.021 18321546
24. A comparative study of a flow cytometry based assessment of in vitro Plasmodium falciparum drug sensitivity. Karl S, Wong RPM, St Pierre TG, Davis TME, Malar J 2009 8 294 10.1186/1475-2875-8-294 20003396
25. Treatment of amoebiasis. Lasserre R, Phil J Microbiol Infect Dis 1979 8 1 1
26. Cardiotoxicity of emetine dihydrochloride by calcium channel blockade in isolated preparations and ventricular myocytes of guinea-pig hearts. Lemmens-Gruber R, Karkhaneh A, Studenik C, Heistracher P, Brit J Pharmacol 1996 117 377 383 10.1111/j.1476-5381.1996.tb15202.x (Pubitemid 26030295)
27. Mechanism of Emetine toxicity. Yang WC, Dubick MW, Pharmacol Ther 1980 10 15 26 10.1016/0163-7258(80)90007-8 6996003 (Pubitemid 10057548)
28. An enzymatic electrocardiographic study on toxicity of dehydroemetine. Dempsey JJ, Salem HH, Brit Heart J 1966 28 505 511 10.1136/hrt.28.4.505 5942470
29. In vitro studies on the sensitivity of local Entamoeba histolytica to anti-amoebic drugs. Chintana T, Sucharit P, Mahakittikun V, Siripanth C, Suphadtanaphongs W, Southeast Asian J Trop Med Public Health 1986 17 591 594 2883732 (Pubitemid 17030772)
30. In vitro activity of antiamoebic drugs against clinical isolates of Entamoeba histolytica and Entamoeba dispar. Bansal D, Sehgal R, Chawla Y, Mahajan RC, Malla N, Ann Clin Microbiol Antimicrob 2004 3 27 31 10.1186/1476-0711-3-27 15610563 (Pubitemid 44650230)
31. In vitro interaction of artemisinin derivatives or the fully synthetic peroxidic antimalarial OZ277 with thapsigargin in P. falciparum strains. Abiodun OO, Brun R, Sergio W, Malar J 2013 12 43 10.1186/1475-2875-12-43 23368889
32. Antimalarial efficacy and drug interactions of the novel semi-synthetic endoperoxide artemisone in vitro and in vivo. Vivas L, Rattray L, Stewart LB, Robinson BL, Fugmann B, Haynes RK, Peters W, Croft SL, J Antimicrob Chemother 2007 59 658 665 10.1093/jac/dkl563 17337512 (Pubitemid 47073399)
33. Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro. Canfield CJ, Pudney M, Gutteridge WE, Exp Parasitol 1995 80 373 381 10.1006/expr.1995.1049 7729473
34. Modified fixed-ratio isbologram method for studying in vitro interactions between atovoquone and proguanil or dihydroartemisinin against drug-resistant strains of Plasmodium falciparum. Fivelman QL, Adagu IS, Warhurst DC, Antimicrob Agents Chemother 2004 48 4097 4102 10.1128/AAC.48.11.4097-4102.2004 15504827 (Pubitemid 39434861)
35. Antimalarial synergism and antagonism. Bennerstrom JL, Ellis WY, Milhouse WK, Eaton RM, Synergism and Antagonism in Chemotherapy New York: Academic Press, Inc, Chou TC, Rideout DC, 2001 183 222
36. Antimalarial synergism and antagonism: mechanistic and clinical significance. Bell A, FEMS Microbiol Lett 2005 253 171 184 10.1016/j.femsle. 2005.09.035 16243458 (Pubitemid 41674513)